Tomahawk, WI 11/19/2013 (BasicsMedia) – Nuvilex Inc (OTCMKTS:NVLX) has had a great year with share prices surging more than 5-10 times compared to its pps in Jan, 2013.  The heavy trading volume on NVLX is suggestive of continued interest from traders and investors. The company’s primary specialty is living cell encapsulation. It was incorporated in 1996 and operates directly and via its subsidiaries. Nuvilex Inc (OTCMKTS:NVLX) uses biotechnology in the development & commercialization of products, specifically living -cell encapsulation in the treatment of large market diseases such as cancer and diabetes. In the last trading session, NVLX traded with more than 1.16M shares in trading volume closing the trading session at $0.125.

[email-download download_id=”1″ contact_form_id=”7511″]

Nuvilex Inc (OTCMKTS:NVLX) operates via numerous subsidiaries. It has acquired the exclusive rights from SG Austria Pte Ltd to use cellulose-based live-encapsulation-technology globally. In 2013, it acquired Bio Blue Bird. SG Austri. Nuvilex Inc (OTCMKTS:NVLX) has also taken on board Medical Marijuana Sciences Inc as the company’s subsidiary in 2013 February. It plans on exploring the use of medicinal -marijuana in the United States. The company has a market capitalization of $79.97 million.

Its three primary segments:

Cancer Treatment: Nuvilex Inc (OTCMKTS:NVLX) has exclusive global rights for live-cell encapsulation-based-platform. It is preparing for the Phase-III clinical trials that are limited to pancreatic cancer.

Diabetes: Nuvilex has acquired exclusive international rights to develop live-encapsulation -technology for diabetes treatment.

Medical Marijuana: In combination with live cell encapsulation therapy, Nuvilex can offer cannabinoid that can suppress pain and improve the line –of-treatment.

Nuvilex Inc (OTCMKTS:NVLX) has made various concerted efforts to ensure that it is making all the right inroads into the biotechnology field. Apart from its latest acquisition, the company is now focused on bolstering its balance sheet. This is one way of ensuring that the company’s broad-based strategy will get the financial backing it needs to gain momentum. The company is:


• Reducing debt in its parent and subsidiary companies. This debt had accrues due to its previous operations and acquisitions.

• Setting the stage for Phase-III trials for the pancreatic treatment. Nuvilex Inc (OTCMKTS:NVLX) has already made astounding progress in this segment.

• The company is also moving forth with expansion into the field of biotechnology via partnership & self research.

• Commercializing products in order to ensure the addition of future revenue streams.

• Developing uses for the company’s products via JV’s, licensing-agreements and contracts

• The expansion and marketing of newly developed products.


Nuvilex Inc (OTCMKTS:NVLX) is currently positioned at a cross -roads of a significant breakthrough. Numerous companies have reached this point but have been unsuccessful. However, Nuvilex has inherent strengths that can help it leverage the conducive market conditions and reach the pinnacle of profitability. The company has a very experienced and qualified management team and innovation and marketing experience are a potent mix. Nuvilex Inc (OTCMKTS:NVLX) also has some path-breaking products in various clinical stages and uses top of the line technology and innovation techniques.

It also has a very clear and concise vision and is taking every step to bolster its finances before moving forth with expansion. This market also has vast potential which is a definite upside for any kind of investment in this industry, at this point of time. The downside is also very less and the company is well set on its path of success.


DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.